CERN Corporation

Microbicidal Light Treatment for Fungal & Bacterial Vaginosis

Claim My Business View on StartEngine
Security Type
Common Stock
Min Investment
Coto de Caza, CA
Offering Date
September 22, 2022
Expected Close Date
December 28, 2022
Amount Raised
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

Cern Corporation, Inc. is pre-revenue. We are developing and commercializing an effective, non-drug therapeutic treatment for fungal and bacterial vaginosis. The Cern Device™ uses low-level microbicidal light to mitigate pathogens associated with yeast and bacterial vaginosis in order to promote a healthy microbiome without the need for drugs. The small, device, similar in size to a tampon, is designed for use at home, as needed when needed, based on familiar symptoms. Development to date includes supportive work performed in vitro, ex vivo as well as in vivo (safety). Current work in microbiology expands our understanding of microbicidal light and it's effects on key pathogens associated with yeast and bacterial indications. Results from test data will be used to develop devices suitable for human use which will be validated in an early feasibility study focused on mechanism of action as efficacious in a human model. Cern has been granted utility and design patents along with trademarks. Cern has also received supportive 3rd part assessment specific to Freedom to Operate. Cern Corporation is currently in the pre-revenue and prototype/testing stages of development.


Select this bonus

$500+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Select this bonus

Friends and Family Early Birds
Invest within the next 72 hours and receive 10% bonus shares.





Select this bonus

$5,000+ Investment
Tier 1
Invest $5,000+ and receive 3% bonus shares

Select this bonus

$10,000+ Investment
Tier 2
Invest $10,000+ and receive 6% bonus shares

Select this bonus

$20,000+ Investment
Tier 3
Invest $20,000+ and receive 10% bonus shares + personal Zoom call with founder/CEO

Key Deal Facts

We believe the Cern Device™ is the only patented Microbicidal Light device for the treatment of fungal, as well as bacterial vaginosis.
The global FemTech Market Size accounted for $46.3B in 2021 and is projected to grow an average CAGR of 13.3% from 2020 till 2025 (source).
Cern has received both utility and design patents along with independent review confirming Freedom to Operate. Our technology and application have been acknowledged by independent science and healthcare experts as what may be a significant break-through for women’s health.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter